Recognizing NIH's Role in Turning Discoveries into Cancer Treatments.

Berna Uygur, Steven Ferguson

Abstract read

In one paragraph

Article in LES nouvelles. Licensing Executives Society (U.S.A.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Berna UygurDivision of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

Steven FergusonOffice of Technology Transfer, National Institutes of Health, Bethesda, Maryland, USA.

Funding

Intramural NIH HHS Z99 OD999999

6 · The paper itself

Abstract

The National Institutes of Health (NIH) has been an engine to transform and move innovative life science ideas to bedside solutions for public health since its establishment in 1887. Led by the National Cancer Institute (NCI), NIH's role in cancer therapeutic development and its largely unseen technology transfer contributions are explored here in three major cancer types: breast, lung, and prostate cancer. The evaluation of publicly available data shows that the NIH, particularly with the activities of NCI, has strongly supported cancer research and has substantially improved public health, saving lives since the 1960s.

Indexed as

cancer death rate improvementcancer drug developmentcollaborationNational Cancer InstituteNational Institutes of Healthtechnology transfer

Identifiers

PMID42211997

PMCPMC13215278

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.